Focal Segmental Glomerulosclerosis Clinical Trial
Official title:
A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
The trial investigates the use of VPA (Valproic Acid) for the treatment of adult patients
with biopsy proven idiopathic focal segmentel glomerulosclerosis (FSGS) or minimal change
disease (MCD).
VPA used as an add-on to steroids might induce clinical remission in a first category of
patients and potentially reduce the dose of maintenance immunosuppression required to
maintain remission thereafter.
In a second category of patients VPA might allow the reduction or even cessation of
immunosuppression while clinical remission is maintained.
Idiopathic MCD to treat diseases with a considerable associated morbidity and mortality.
Current treatment options are limited, have limited efficacy and a considerable side effect
profile. Recent findings in a murine model suggest that VPA treatment in an early phase of
renal disease could halt or even prevent the development of proteinuria and the progression
of kidney damage. VPA is a commonly used and easy available oral antiepileptic agent with a
favorable side effect profile compared to the current standard of care agents for
podocytopathies.
This trial investigates wether
1. VPA on top of or in substitution of standard of care agents is effective in remission
induction in patients with FSGS or MCD with proteinuria resistant to first line therapy
with corticosteroids.
2. VPA is effective in remission maintenance allowing reduction and cessation of chronic
immunosuppression without relapse in patients with frequently relapsing FSGS or MCD.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02585804 -
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
|
Phase 4 | |
| Not yet recruiting |
NCT00956059 -
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
|
N/A | |
| Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
| Recruiting |
NCT05583942 -
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
|
N/A | |
| Recruiting |
NCT05588063 -
taVNS for FRNS in Children
|
N/A | |
| Completed |
NCT04369183 -
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
|
||
| Completed |
NCT01113385 -
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
|
N/A | |
| Terminated |
NCT00883636 -
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
|
N/A | |
| Completed |
NCT04009668 -
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
|
Phase 2 | |
| Terminated |
NCT03703908 -
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
|
Phase 2 | |
| Completed |
NCT03649152 -
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
|
Phase 2 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Completed |
NCT00255398 -
Kidney Disease Biomarkers
|
||
| Terminated |
NCT05441826 -
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
|
Phase 2 | |
| Recruiting |
NCT02235857 -
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
|
N/A | |
| Recruiting |
NCT05942625 -
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT02382874 -
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
|
Phase 1 | |
| Completed |
NCT00464321 -
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
|
Phase 1 | |
| Completed |
NCT03536754 -
A Study of CCX140-B in Subjects With FSGS
|
Phase 2 | |
| Recruiting |
NCT03929887 -
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
|